Arena is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors (GPCRs) to address unmet medical needs.
Our internally discovered and developed drug for weight management, BELVIQ® (lorcaserin HCl), was launched in the United States in 2013 and approved in South Korea in early 2015. Following are links to certain additional information:
We have granted exclusive marketing and distribution rights for BELVIQ to Eisai Inc. and Eisai Co., Ltd., for most territories worldwide; to Ildong Pharmaceutical Co., Ltd., for South Korea; to CY Biotech Company Limited for Taiwan; and to Teva Pharmaceutical Industries Ltd.’s local Israeli subsidiary for Israel.
We will explore with our collaborators or independently BELVIQ’s therapeutic potential for additional indications, in other formulations and in combination with other drugs.
We are utilizing our validated research and development approach to advance our pipeline of internally discovered, oral drug candidates.